Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARA | P10276 | 1/20 | 0.57 |
| ▸ | RARB | P10826 | 1/20 | 0.57 |
| ▸ | RARG | P13631 | 1/20 | 0.57 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 5/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | ACLY | P53396 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10352726 | 0.90 | RARA (0.61) | RARARARBRARGHPGDKDM4E | |
| SCHEMBL28744670 | 0.84 | ABCB1 (0.50) | HPGDKDM4EALDH1A1MAPTKMT2A | |
| SCHEMBL28115368 | 0.84 | GAA (0.56) | RARARARBRARGHPGDALDH1A1 | |
| SCHEMBL380317 | 0.82 | RARA (0.41) | RARARARBRARGHTR2CHPGD | |
| SCHEMBL14580105 | 0.80 | RARA (0.60) | RARARARBRARGHPGDMAPT | |
| SCHEMBL2535026 | 0.80 | RARB (0.43) | RARARARBRARGMAPTKMT2A | |
| SCHEMBL25602482 | 0.78 | RARA (0.58) | RARARARBRARGALDH1A1MAPT | |
| SCHEMBL4533772 | 0.78 | L3MBTL1 (0.62) | HPGDKDM4EALDH1A1MAPTKMT2A | |
| SCHEMBL27991629 | 0.78 | RXRA (0.42) | RARBRARGHPGDKDM4EALDH1A1 | |
| SCHEMBL9077062 | 0.77 | RARA (0.56) | RARARARBRARGHPGDKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11046680-B1 | Heteroaryl-substituted triazoles as APJ receptor agonists | AMGEN INC. (US) | 2021-06-29 | — | — | US | disclosed |
| US-10906890-B2 | Triazole phenyl compounds as agonists of the APJ receptor | AMGEN INC. (US) | 2021-02-02 | — | — | US | disclosed |
| US-20200339530-A1 | UREA DERIVATIVES AS INHIBITORS OF ASK1 | HEPAGENE THERAPEUTICS, INC. (VG) | 2020-10-29 | — | — | US | disclosed |
| US-20190284173-A1 | TRIAZOLE PHENYL COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AMGEN INC. (US) | 2019-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190284173-A1 | TRIAZOLE PHENYL COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AGTR1, AGTR2, TBXA2R | RARA 540/4885RARB 582/4885RARG 511/4885 |
| US-11046680-B1 | Heteroaryl-substituted triazoles as APJ receptor agonists | AGTR1, AGTR2, TBXA2R | RARA 654/4885RARB 717/4885RARG 612/4885 |
| US-10906890-B2 | Triazole phenyl compounds as agonists of the APJ receptor | AGTR1, AGTR2, TBXA2R | RARA 540/4885RARB 582/4885RARG 511/4885 |
| US-20200339530-A1 | UREA DERIVATIVES AS INHIBITORS OF ASK1 | ATF1, ERN1, MAP3K1 | RARA 4240/4885RARB 3645/4885RARG 4198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.